Published Jun 12, 2019

Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development

Member News
The MoU was signed during the official, 40thanniversary celebration ceremony of the Shanghai-Rotterdam Sister City Relationship.

Related or similar articles

December 10, 2021

Labshares Newton Doubles Space for Emerging Biotech Startups

NEWTON, Mass.--(BUSINESS WIRE)--Labshares Newton celebrated today the opening of 19,000 square feet of new incubator lab space and expects to open another 6,000-foot lab in September. Labshares’ new space incorporates 12 private suites, 15 lab ...
Labshares News
August 19, 2019

Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma

Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...
Member News
April 28, 2020

Labshares Newton Awards Free Project-Based Lab Space to Three Innovative Diagnostics Companies Conducting COVID-19 Research​

Labshares Newton, a shared office and laboratory incubator for emerging biotechnology and life science companies, today announced that it has selected three startup companies developing COVID-19 diagnostics to receive free lab space. The companies...
Labshares News